|
9.10.2014 |
EN |
Official Journal of the European Union |
C 356/22 |
Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2012
2014/C 356/07
Subcommittee I on the free movement of goods
To be noted by the EEA Joint Committee
With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January-30 June 2012, at their meeting on 15 July 2013:
|
Annex I |
List of new marketing authorisations |
|
Annex II |
List of renewed marketing authorisations |
|
Annex III |
List of extended marketing authorisations |
|
Annex IV |
List of withdrawn marketing authorisations |
|
Annex V |
List of suspended marketing authorisations |
ANNEX I
List of new marketing authorisations
The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January-30 June 2012:
|
EU-Number |
Product |
Country |
Date of authorisation |
|
EU/1/11/711/001-030 |
Matever |
Norway |
1.6.2012 |
|
EU/1/11/712/001-028 |
Levetiracetam Accord |
Norway |
13.4.2012 |
|
EU/1/11/713/001-040 |
Levetiracetam Actavis |
Norway |
16.4.2012 |
|
EU/1/11/715/001-002 |
Plenadren |
Iceland |
23.4.2012 |
|
EU/1/11/721/001-021 |
Paglitaz |
Norway |
13.4.2012 |
|
EU/1/11/721/001-021 |
Paglitaz |
Iceland |
17.4.2012 |
|
EU/1/11/722/001-030 |
Pioglitazone Accord |
Norway |
11.4.2012 |
|
EU/1/11/722/001-030 |
Pioglitazon Accord |
Liechtenstein |
30.4.2012 |
|
EU/1/11/722/001-030 |
Pioglitazone Accord |
Iceland |
20.4.2012 |
|
EU/1/11/723/001-021 |
Pioglitazone Krka |
Norway |
23.5.2012 |
|
EU/1/11/723/001-021 |
Pioglitazone Krka |
Iceland |
20.4.2012 |
|
EU/1/11/727/001 |
Mercatopurine Nova lab. |
Norway |
19.4.2012 |
|
EU/1/11/727/001 |
Mercaptopurine Nova Laboratories |
Iceland |
3.4.2012 |
|
EU/1/11/727/001 |
Mercatopurine Nova Laboratories |
Liechtenstein |
30.4.2012 |
|
EU/1/11/729/001-006 |
Onduarp |
Norway |
8.5.2012 |
|
EU/1/11/730/001-060 |
Rasitrio |
Iceland |
3.2.2012 |
|
EU/1/11/738/001-003 |
Levetiracetam Actavis Gr. |
Norway |
1.3.2012 |
|
EU/1/11/739/001-008 |
Dasselta |
Norway |
16.1.2012 |
|
EU/1/11/740/001 |
Ameluz |
Iceland |
5.1.2012 |
|
EU/1/11/740/001 |
Ameluz |
Norway |
16.1.2012 |
|
EU/1/11/741/001 |
Levetiracetam SUN |
Norway |
27.1.2012 |
|
EU/1/11/741/001 |
Levetiracetam Sun |
Iceland |
9.1.2012 |
|
EU/1/11/742/001-010 |
Efavirenz Teva |
Norway |
13.2.2012 |
|
EU/1/11/742/001-010 |
Efavirenz Teva |
Iceland |
24.1.2012 |
|
EU/1/11/742/001-010 |
Efavirenz Teva |
Liechtenstein |
29.2.2012 |
|
EU/1/11/743/001-015 |
Repaglinide Accord |
Norway |
13.2.2012 |
|
EU/1/11/743/001-015 |
Repaglinide Accord |
Iceland |
19.1.2012 |
|
EU/1/11/743/001-015 |
Repaglinide Accord |
Liechtenstein |
29.2.2012 |
|
EU/1/11/744/001-002 |
Topotecan Eagle |
Iceland |
22.1.2012 |
|
EU/1/11/744/001-002 |
Topotecan Eagle |
Liechtenstein |
29.2.2012 |
|
EU/1/11/745/001-009 |
Desloratadine Actavis |
Iceland |
3.2.2012 |
|
EU/1/11/745/001-009 |
Desloratadine Actavis |
Norway |
13.2.2012 |
|
EU/1/11/746/001-012 |
Desloratadine ratiopharm |
Norway |
13.2.2012 |
|
EU/1/11/746/001-012 |
Desloratadine ratiopharm |
Iceland |
3.2.2012 |
|
EU/1/11/746/001-012 |
Desloratadine ratiopharm |
Liechtenstein |
29.2.2012 |
|
EU/1/11/747/001 |
Colobreathe |
Iceland |
29.2.2012 |
|
EU/1/11/747/001 |
Colobreathe |
Liechtenstein |
29.2.2012 |
|
EU/1/11/748/001-006 |
Docetaxel Mylan |
Iceland |
7.2.2012 |
|
EU/1/11/748/001-006 |
Docetaxel Mylan |
Liechtenstein |
29.2.2012 |
|
EU/1/11/749/001-002 |
Caprelsa |
Liechtenstein |
30.4.2012 |
|
EU/1/11/749/001-003 |
Caprelsa |
Iceland |
9.3.2012 |
|
EU/1/11/749/001-002 |
Caprelsa |
Norway |
13.3.2012 |
|
EU/1/12/750/001 |
Esmya |
Norway |
30.3.2012 |
|
EU/1/12/750/001 |
Esmya |
Iceland |
14.3.2012 |
|
EU/1/12/750/001 |
Esmya |
Liechtenstein |
30.4.2012 |
|
EU/1/12/751/001 |
Zelboraf |
Norway |
14.3.2012 |
|
EU/1/12/751/001 |
Zelboraf |
Iceland |
7.3.2012 |
|
EU/1/12/751/001 |
Zelboraf |
Liechtenstein |
29.2.2012 |
|
EU/1/12/752/001 |
Vepacel |
Norway |
1.3.2012 |
|
EU/1/12/752/001 |
Vepacel |
Iceland |
9.3.2012 |
|
EU/1/12/752/001 |
Vepacel |
Liechtenstein |
29.2.2012 |
|
EU/1/12/753/001-012 |
Signifor |
Norway |
10.5.2012 |
|
EU/1/12/753/001-012 |
Signifor |
Iceland |
24.5.2012 |
|
EU/1/12/753/001-012 |
Signifor |
Liechtenstein |
30.6.2012 |
|
EU/1/12/754/001-021 |
Sepioglin |
Norway |
10.4.2012 |
|
EU/1/12/754/001-021 |
Sepioglin |
Iceland |
3.4.2012 |
|
EU/1/12/754/001-021 |
Sepioglin |
Liechtenstein |
30.4.2012 |
|
EU/1/12/755/001-027 |
Pioglitazone Actavis |
Norway |
13.4.2012 |
|
EU/1/12/755/001-027 |
Pioglitazone Actavis |
Iceland |
30.4.2012 |
|
EU/1/12/756/001-027 |
Glidipion (ex Ogliton) |
Norway |
13.4.2012 |
|
EU/1/12/756/001-027 |
Pioglitazone Actavis Group |
Iceland |
13.4.2012 |
|
EU/1/12/756/001-027 |
Pioglitazone Actavis Group |
Liechtenstein |
30.4.2012 |
|
EU/1/12/757/001-030 |
Pioglitazone Teva |
Norway |
11.4.2012 |
|
EU/1/12/757/001-030 |
Pioglitazone Teva |
Iceland |
23.4.2012 |
|
EU/1/12/758/001-030 |
Pioglitazone Teva Pharma |
Norway |
17.4.2012 |
|
EU/1/12/758/001-030 |
Pioglitazone Teva Pharma |
Iceland |
25.4.2012 |
|
EU/1/12/759/001-003 |
Zoledronic acid Actavis |
Norway |
8.5.2012 |
|
EU/1/12/759/001-003 |
Zoledronic acid Actavis |
Iceland |
16.5.2012 |
|
EU/1/12/759/001-003 |
Zoledronsäure Actavis |
Liechtenstein |
30.4.2012 |
|
EU/1/12/760/001-002 |
Bronchitol |
Norway |
18.5.2012 |
|
EU/1/12/760/001-002 |
Bronchitol |
Iceland |
9.5.2012 |
|
EU/1/12/761/001-002 |
Capecitabine Teva |
Norway |
30.5.2012 |
|
EU/1/12/761/001-002 |
Capecitabine Teva |
Iceland |
20.5.2012 |
|
EU/1/12/761/001-002 |
Capecitabin Teva |
Liechtenstein |
30.4.2012 |
|
EU/1/12/762/001-018 |
Capecitabine Accord |
Iceland |
20.5.2012 |
|
EU/1/12/762/001-018 |
Capecitabin Accord |
Liechtenstein |
30.4.2012 |
|
EU/1/12/763/001-018 |
Capecitabine Krka |
Iceland |
16.5.2012 |
|
EU/1/12/763/001-018 |
Capecitabin Krka |
Liechtenstein |
30.4.2012 |
|
EU/1/12/763/001-018 |
Capecitabine Krka |
Norway |
14.6.2012 |
|
EU/1/12/764/001 |
Pixuvri |
Norway |
14.6.2012 |
|
EU/1/12/764/001 |
Pixuvri |
Iceland |
29.5.2012 |
|
EU/1/12/764/001 |
Pixuvri |
Liechtenstein |
30.6.2012 |
|
EU/1/12/765/001-004 |
Sabervel |
Iceland |
9.5.2012 |
|
EU/1/12/765/001-006 |
Sabervel |
Norway |
8.5.2012 |
|
EU/1/12/765/001-006 |
Sabervel |
Liechtenstein |
30.4.2012 |
|
EU/1/12/766/001 |
Sancuso |
Norway |
10.5.2012 |
|
EU/1/12/766/001 |
Sancuso |
Iceland |
20.5.2012 |
|
EU/1/12/766/001 |
Sancuso |
Liechtenstein |
30.6.2012 |
|
EU/1/12/767/001-007 |
Nimenrix |
Norway |
1.5.2012 |
|
EU/1/12/767/001-007 |
Nimenrix |
Iceland |
16.5.2012 |
|
EU/1/12/768/001 |
Riluzole Zentiva |
Iceland |
25.5.2012 |
|
EU/1/12/768/001 |
Riluzol Zentiva |
Liechtenstein |
30.6.2012 |
|
EU/1/12/769/001-003 |
Docetaxel Accord |
Iceland |
12.6.2012 |
|
EU/1/12/769/001-003 |
Docetaxel Accord |
Liechtenstein |
30.6.2012 |
|
EU/1/12/770/001-004 |
Docetaxel Kabi |
Norway |
19.6.2012 |
|
EU/1/12/770/001-004 |
Docetaxel Kabi |
Iceland |
13.6.2012 |
|
EU/1/12/770/001-004 |
Docetaxel Kabi |
Liechtenstein |
30.6.2012 |
|
EU/2/11/134/001-014 |
Inflacam |
Norway |
6.1.2012 |
|
EU/2/11/135/001-003 |
Panacur AquaSol |
Norway |
10.2.2012 |
|
EU/2/11/136/001 |
Truscient |
Norway |
6.1.2012 |
|
EU/2/11/136/001 |
TruScient |
Iceland |
12.1.2012 |
|
EU/2/11/137/001-015 |
Activyl Tick Plus |
Norway |
13.2.2012 |
|
EU/2/11/137/001-015 |
Activyl Tick Plus |
Iceland |
25.1.2012 |
|
EU/2/11/137/001-015 |
Activyl Tick Plus |
Liechtenstein |
29.2.2012 |
|
EU/2/12/138/001-003 |
RevitaCAM |
Iceland |
14.3.2012 |
|
EU/2/12/139/001-003 |
Zulvac 1 + 8 Bovis |
Norway |
3.4.2012 |
|
EU/2/12/139/001-003 |
Zulvac 1 + 8 Bovis |
Iceland |
4.4.2012 |
|
EU/2/12/139/001-003 |
Zulvac 1 + 8 Bovis |
Liechtenstein |
30.4.2012 |
ANNEX II
List of renewed marketing authorisations
The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January-30 June 2012:
|
EU-Number |
Product |
Country |
Date of authorisation |
|
EU/1/01/197/001-005 |
Foscan |
Iceland |
14.5.2012 |
|
EU/1/01/200/001-002 |
Viread |
Norway |
6.1.2012 |
|
EU/1/01/200/001-002 |
Viread |
Iceland |
5.1.2012 |
|
EU/1/02/209/001-008 |
Dynastat |
Norway |
8.3.2012 |
|
EU/1/02/209/001-008 |
Dynastat |
Iceland |
7.2.2012 |
|
EU/1/02/209/001-008 |
Dynastat |
Liechtenstein |
29.2.2012 |
|
EU/1/02/212/001-026 |
Vfend |
Norway |
6.3.2012 |
|
EU/1/02/212/001-026 |
Vfend |
Iceland |
14.3.2012 |
|
EU/1/02/212/001-026 |
Vfend |
Liechtenstein |
30.4.2012 |
|
EU/1/02/216/001-002 |
Invanz |
Norway |
19.1.2012 |
|
EU/1/02/216/001-002 |
Invanz |
Iceland |
20.1.2012 |
|
EU/1/02/216/001-002 |
Invanz |
Liechtenstein |
29.2.2012 |
|
EU/1/02/220/001-006 |
Tracleer |
Norway |
8.5.2012 |
|
EU/1/02/220/001-006 |
Tracleer |
Iceland |
20.5.2012 |
|
EU/1/02/220/001-006 |
Tracleer |
Liechtenstein |
30.4.2012 |
|
EU/1/02/222/001-005 |
Tamiflu |
Norway |
8.3.2012 |
|
EU/1/02/222/001-005 |
Tamiflu |
Iceland |
19.6.2012 |
|
EU/1/02/222/001-005 |
Tamiflu |
Liechtenstein |
30.6.2012 |
|
EU/1/06/334/001-005 |
Evoltra |
Liechtenstein |
30.4.2012 |
|
EU/1/06/347/001-008 |
Sutent |
Liechtenstein |
29.2.2012 |
|
EU/1/06/366/005-022 |
Tandemact |
Norway |
11.4.2012 |
|
EU/1/06/366/005-022 |
Tandemact |
Iceland |
22.3.2012 |
|
EU/1/06/366/005-022 |
Tandemact |
Liechtenstein |
30.4.2012 |
|
EU/1/06/367/001-012 |
Diacomit |
Norway |
6.3.2012 |
|
EU/1/06/367/001-012 |
Diacomit |
Iceland |
7.2.2012 |
|
EU/1/06/367/001-012 |
Diacomit |
Liechtenstein |
29.2.2012 |
|
EU/1/06/370/001-039 |
Exforge |
Norway |
16.1.2012 |
|
EU/1/06/370/001-039 |
EXFORGE |
Iceland |
3.2.2012 |
|
EU/1/06/371/001-039 |
Dafiro |
Iceland |
8.2.2012 |
|
EU/1/06/371/001-039 |
Dafiro |
Liechtenstein |
29.2.2012 |
|
EU/1/06/372/001-039 |
Copalia |
Norway |
11.1.2012 |
|
EU/1/06/373/001-039 |
Imprida |
Norway |
16.1.2012 |
|
EU/1/06/373/001-039 |
Imprida |
Iceland |
6.2.2012 |
|
EU/1/06/374/001 |
Lucentis |
Norway |
17.1.2012 |
|
EU/1/06/374/001 |
Lucentis |
Iceland |
12.1.2012 |
|
EU/1/06/376/001-033 |
Irbesartan Zentiva (ex-Winthrop) |
Norway |
14.2.2012 |
|
EU/1/06/376/001-033 |
Irbesartan Zentiva |
Iceland |
7.2.2012 |
|
EU/1/06/376/001-033 |
Irbesartan Winthrop |
Liechtenstein |
29.2.2012 |
|
EU/1/06/377/001-028 |
Irbesartan HCT Zentiva (ex-Winthrop) |
Norway |
16.4.2012 |
|
EU/1/06/377/001-028 |
Irbesartan HCT Zentiva |
Iceland |
22.3.2012 |
|
EU/1/06/377/001-028 |
Irbesartan HCT |
Liechtenstein |
30.4.2012 |
|
EU/1/06/378/001-017 |
Inovelon |
Norway |
6.3.2012 |
|
EU/1/06/378/001-017 |
Inovelon |
Iceland |
24.1.2012 |
|
EU/1/06/378/001-017 |
Inovelon |
Liechtenstein |
29.2.2012 |
|
EU/1/06/379/001 |
Cystadane |
Iceland |
9.3.2012 |
|
EU/1/06/379/001 |
Cystadane |
Liechtenstein |
29.2.2012 |
|
EU/1/06/386/001-015, 020-024, 029-033, 038-042, 047-051, 056-057, 088102, 113-150, 163-168 |
Insulin Human Winthrop |
Norway |
6.1.2012 |
|
EU/1/07/382/001-018 |
Xelevia |
Norway |
14.2.2012 |
|
EU/1/07/382/001-018 |
Xelevia |
Iceland |
6.2.2012 |
|
EU/1/07/382/001-018 |
Xelevia |
Liechtenstein |
29.2.2012 |
|
EU/1/07/383/001-018 |
Januvia |
Norway |
26.3.2012 |
|
EU/1/07/383/001-018 |
Januvia |
Iceland |
11.5.2012 |
|
EU/1/07/383/001-018 |
Januvia |
Liechtenstein |
30.4.2012 |
|
EU/1/07/384/003-005 |
Docetaxel Winthrop |
Norway |
10.4.2012 |
|
EU/1/07/384/003-005 |
Docetaxel Winthrop |
Iceland |
23.3.2012 |
|
EU/1/07/384/003-005 |
Docetaxel Winthrop |
Liechtenstein |
30.4.2012 |
|
EU/1/07/386/001-018 |
Toviaz |
Norway |
11.4.2012 |
|
EU/1/07/386/001-018 |
Toviaz |
Iceland |
10.4.2012 |
|
EU/1/07/386/001-018 |
Toviaz |
Liechtenstein |
30.4.2012 |
|
EU/1/07/387/001-026 |
Advagraf |
Norway |
2.5.2012 |
|
EU/1/07/387/001-026 |
Advagraf |
Iceland |
9.5.2012 |
|
EU/1/07/387/001-026 |
Advagraf |
Liechtenstein |
30.4.2012 |
|
EU/1/07/388/001-003 |
Sebivo |
Norway |
8.5.2012 |
|
EU/1/07/388/001-003 |
Sebivo |
Iceland |
16.5.2012 |
|
EU/1/07/388/001-003 |
Sebivo |
Liechtenstein |
30.4.2012 |
|
EU/1/07/389/001-003 |
Orencia |
Norway |
10.4.2012 |
|
EU/1/07/389/001-003 |
Orencia |
Iceland |
10.4.2012 |
|
EU/1/07/389/001-003 |
Orencia |
Liechtenstein |
30.4.2012 |
|
EU/1/07/390/001-004 |
Altargo |
Norway |
8.5.2012 |
|
EU/1/07/390/001-004 |
Altargo |
Iceland |
16.5.2012 |
|
EU/1/07/390/001-004 |
Altargo |
Liechtenstein |
30.4.2012 |
|
EU/1/07/391/001-004 |
Revlimid |
Norway |
3.5.2012 |
|
EU/1/07/391/001-004 |
Revlimid |
Iceland |
9.5.2012 |
|
EU/1/07/391/001-004 |
Revlimid |
Liechtenstein |
30.4.2012 |
|
EU/1/07/392/001-003 |
Circadin |
Norway |
16.5.2012 |
|
EU/1/07/392/001-003 |
Circadin |
Iceland |
10.5.2012 |
|
EU/1/07/392/001-003 |
Circadin |
Liechtenstein |
30.6.2012 |
|
EU/1/07/394/001-009 |
Optaflu |
Norway |
20.6.2012 |
|
EU/1/07/395/001-095 |
Invega |
Liechtenstein |
30.6.2012 |
|
EU/1/07/396/001-003 |
Pergoveris |
Iceland |
20.6.2012 |
|
EU/1/07/396/001-003 |
Pergoveris |
Liechtenstein |
30.6.2012 |
|
EU/1/07/398/001-014 |
Optimark |
Norway |
27.6.2012 |
|
EU/1/07/399/001-006 |
Aerinaze |
Norway |
18.6.2012 |
|
EU/1/07/399/001-006 |
Aerinaze |
Liechtenstein |
30.6.2012 |
|
EU/1/07/399/001-006 |
Aerinaze |
Iceland |
20.6.2012 |
|
EU/1/07/400/008-013, 017-024 |
Mircera |
Iceland |
7.6.2012 |
|
EU/1/07/400/008-013, 017-024 |
Mircera |
Norway |
14.6.2012 |
|
EU/1/07/400/017-024 |
Mircera |
Liechtenstein |
30.6.2012 |
|
EU/1/07/401/007-016 |
alli |
Norway |
29.6.2012 |
|
EU/1/07/412/001-052 |
Abseamed |
Liechtenstein |
30.6.2012 |
|
EU/1/07/423/001-003 |
Vectibix |
Norway |
19.3.2012 |
|
EU/1/07/423/001-003 |
Vectibix |
Iceland |
9.3.2012 |
|
EU/1/07/440/001-003 |
Tyverb |
Liechtenstein |
30.4.2012 |
|
EU/1/07/440/001-006 |
Tyverb |
Norway |
2.5.2012 |
|
EU/1/07/440/001-006 |
Tyverb |
Iceland |
11.5.2012 |
|
EU/1/10/625/001&003 |
Arzerra |
Iceland |
17.2.2012 |
|
EU/1/10/625/001&003 |
Arzerra |
Norway |
18.5.2012 |
|
EU/1/10/628/001-004 |
Votrient |
Norway |
19.6.2012 |
|
EU/1/10/628/001-004 |
Votrient |
Iceland |
13.6.2012 |
|
EU/1/11/699/001-004 |
Fampyra |
Norway |
19.6.2012 |
|
EU/1/11/699/001-004 |
Fampyra |
Iceland |
13.6.2012 |
|
EU/1/11/699/001-004 |
Fampyra |
Liechtenstein |
30.6.2012 |
|
EU/2/05/053/001-003 |
Naxcel |
Norway |
14.2.2012 |
|
EU/2/06/068/001-004 |
Ypozane |
Norway |
13.2.2012 |
|
EU/2/06/068/001-004 |
Ypozane |
Iceland |
18.1.2012 |
|
EU/2/06/068/001-004 |
Ypozane |
Liechtenstein |
30.4.2012 |
|
EU/2/06/070/001-008 |
Meloxidyl |
Iceland |
13.1.2012 |
|
EU/2/07/071/001-003 |
SLENTROL |
Iceland |
7.5.2012 |
|
EU/2/07/071/001-003 |
Slentrol |
Liechtenstein |
30.4.2012 |
|
EU/2/07/072/001-004 |
Suprelorin |
Iceland |
21.6.2012 |
|
EU/2/07/074/001-006 |
Prilactone |
Iceland |
13.6.2012 |
|
EU/2/07/075/001-004 |
Circovac |
Liechtenstein |
30.6.2012 |
|
EU/2/07/075/001-004 |
Circovac |
Iceland |
4.6.2012 |
ANNEX III
List of extended marketing authorisations
The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January-30 June 2012:
|
EU-Number |
Product |
Country |
Date of authorisation |
|
EU/1/00/141/002 |
Myocet |
Liechtenstein |
30.4.2012 |
|
EU/1/02/222/05 |
Tamiflu |
Iceland |
6.2.2012 |
|
EU/1/03/262/009-010 |
Emend |
Norway |
5.1.2012 |
|
EU/1/03/262/009-010 |
Emend |
Iceland |
3.2.2012 |
|
EU/1/03/271/007-010 |
Advate |
Norway |
23.1.2012 |
|
EU/1/03/271/007-010 |
Advate |
Iceland |
17.1.2012 |
|
EU/1/05/318/003 |
Revatio |
Norway |
13.4.2012 |
|
EU/1/05/318/003 |
Revatio |
Iceland |
17.4.2012 |
|
EU/1/05/318/003 |
Revatio |
Liechtenstein |
30.4.2012 |
|
EU/1/06/339/003 |
Preotact |
Liechtenstein |
30.6.2012 |
|
EU/1/08/465/021 |
Clopidogrel Zentiva |
Liechtenstein |
30.6.2012 |
|
EU/1/08/468/002 |
INTELENCE |
Iceland |
3.1.2012 |
|
EU/1/08/470/018-019 |
Vimpat |
Norway |
14.3.2012 |
|
EU/1/08/470/018-019 |
Vimpat |
Iceland |
14.3.2012 |
|
EU/1/08/470/018-019 |
Vimpat |
Liechtenstein |
30.4.2012 |
|
EU/1/08/472/011-021 |
Xarelto |
Norway |
4.1.2012 |
|
EU/1/08/475/035-060 |
Olanzapin Mylan |
Liechtenstein |
29.2.2012 |
|
EU/1/09/536/003-004 |
Topotecan Actavis |
Liechtenstein |
30.4.2012 |
|
EU/1/09/551/013-027 |
Vizarsin |
Iceland |
7.6.2012 |
|
EU/1/09/551/013-027 |
Vizarsin |
Liechtenstein |
30.6.2012 |
|
EU/1/09/571/002 |
Pandemic influenza vaccine H5N1 Baxter |
Liechtenstein |
30.4.2012 |
|
EU/1/11/667/004 |
Esbriet |
Liechtenstein |
30.4.2012 |
|
EU/1/11/699/003-004 |
Fampyra |
Liechtenstein |
30.4.2012 |
|
EU/1/11/701/029-032 |
Levetiracetam Teva |
Liechtenstein |
30.6.2012 |
|
EU/1/11/703/003 |
Xgeva |
Liechtenstein |
29.2.2012 |
|
EU/1/11/704/002 |
Victrelis |
Liechtenstein |
30.4.2012 |
|
EU/1/11/720/002 |
Incivo |
Liechtenstein |
30.6.2012 |
|
EU/1/97/044/009 |
Tasmar |
Liechtenstein |
30.4.2012 |
|
EU/2/07/078/015-017 |
Rheumocam |
Norway |
13.2.2012 |
|
EU/2/07/078/015-017 |
Rheumocam |
Iceland |
7.2.2012 |
|
EU/2/07/078/015-017 |
Rheumocam |
Liechtenstein |
29.2.2012 |
|
EU/2/08/085/002-006 |
Easotic |
Liechtenstein |
30.4.2012 |
|
EU/2/08/090/027 |
Loxicom |
Liechtenstein |
30.6.2012 |
|
EU/2/10/114/003 |
Hiprabovis IBR Marker Live |
Liechtenstein |
29.2.2012 |
|
EU/2/97/004/049 |
Metacam |
Liechtenstein |
29.2.2012 |
ANNEX IV
List of withdrawn marketing authorisations
The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January-30 June 2012:
|
EU-Number |
Product |
Country |
Date of authorisation |
|
EU/1/02/255/001-002 |
Xigris |
Iceland |
25.6.2012 |
|
EU/1/04/272/001-002 |
PhotoBarr |
Norway |
24.5.2012 |
|
EU/1/04/272/001-002 |
Photobarr |
Iceland |
20.5.2012 |
|
EU/1/04/272/001-002 |
PhotoBarr |
Liechtenstein |
30.6.2012 |
|
EU/1/06/335/001 |
Valtropin |
Iceland |
5.6.2012 |
|
EU/1/06/335/001 |
Valtropin |
Liechtenstein |
30.6.2012 |
|
EU/1/06/351/001-003 |
Livensa |
Iceland |
11.4.2012 |
|
EU/1/06/351/001-003 |
Livensa |
Liechtenstein |
30.4.2012 |
|
EU/1/06/352/001-003 |
Intrinsa |
Liechtenstein |
30.6.2012 |
|
EU/1/06/352/001-003 |
Intrinsa |
Iceland |
23.6.2012 |
|
EU/1/09/534/001-007 |
Clopidogrel Hexal |
Iceland |
2.3.2012 |
|
EU/1/09/534/001-007 |
Clopidgrel Hexal |
Liechtenstein |
29.2.2012 |
|
EU/1/09/548/001-007 |
Clopidogrel Acino Pharma GmbH |
Iceland |
2.3.2012 |
|
EU/1/09/548/001-007 |
Clopidgrel Acino Pharma GmbH |
Liechtenstein |
29.2.2012 |
|
EU/1/09/549/001-007 |
Clopidogrel Acino Pharma |
Iceland |
2.3.2012 |
|
EU/1/09/549/001-007 |
Clopidogrel Acino Pharma |
Liechtenstein |
29.2.2012 |
|
EU/1/10/630/001-002 |
Docefrez |
Iceland |
20.6.2012 |
|
EU/1/10/630/001-002 |
Docefrez |
Liechtenstein |
30.6.2012 |
|
EU/1/97/035/003-004 |
Refludan |
Iceland |
24.5.2012 |
|
EU/1/97/035/001-004 |
Refludan |
Norway |
6.6.2012 |
|
EU/1/97/035/001-004 |
Refludan |
Liechtenstein |
30.6.2012 |
|
EU/2/00/028/002-008 |
Zubrin |
Iceland |
17.4.2012 |
|
EU/2/00/028/002-008 |
Zubrin |
Liechtenstein |
30.4.2012 |
|
EU/2/03/040/001-002 |
Gonazon |
Norway |
2.4.2012 |
|
EU/2/03/040/001-002 |
Gonazon |
Iceland |
17.4.2012 |
|
EU/2/03/040/001-002 |
Gonazon |
Liechtenstein |
30.4.2012 |
|
EU/2/06/060/001-002 |
Poulvac FluFend H5N3 RG |
Liechtenstein |
30.6.2012 |
ANNEX V
List of suspended marketing authorisations
The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January-30 June 2012:
|
EU-Number |
Product |
Country |
Date of authorisation |
|
EU/1/06/361/001-002 |
Luminity |
Iceland |
20.6.2012 |
|
EU/1/06/361/001-002 |
Luminity |
Liechtenstein |
30.6.2012 |
|
EU/1/97/037/001 |
Vistide |
Liechtenstein |
29.2.2012 |
|
EU/1/11/705/001 |
Vibativ |
Iceland |
27.6.2012 |